- Home
- »
- Pharmaceuticals
- »
-
Parkinson's Disease Treatment Market Size Report, 2033GVR Report cover
Parkinson’s Disease Treatment Market (2026 - 2033)
Size, Share & Trends Analysis Report By Drug Class (Carbidopa-Levodopa, MAO-B Inhibitors, COMT inhibitors, Anticholinergics), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Region, And Segment Forecasts
Market Size, 2025
$5.6BMarket Estimate, 2026
$6.3BMarket Forecast, 2033
$14.2BCAGR, 2026–2033
12.3%Parkinson's Disease Treatment Market Summary
The global parkinson’s disease treatment market size was valued at USD 5.6 billion in 2025 and is projected to grow from USD 6.3 billion in 2026 to USD 14.2 billion by 2033, at a CAGR of 12.3% from 2026 to 2033. North America dominated the market, accounting for the largest global share of 38.1% in 2025. The market experiences growth due to increasing global prevalence, driven by aging populations and enhanced diagnostic capabilities.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,
Download Free Sample Report Key Market Trends & Insights
- By drug class: Carbidopa-levodopa segment held the largest revenue share of 28.6% in 2025.
- By distribution channel: Retail pharmacy segment held the largest revenue share of 41.7% in 2025.
Regional Highlights
- Largest regional market: North America (38.1% revenue share, 2025)
- By country: The U.S. held the largest share of North America in 2025.
Market Size & Forecast
- Market size in 2025: USD 5.6 Billion
- Estimated market size in 2026: USD 6.3 Billion
- Projected market size by 2033: USD 14.2 Billion
- CAGR (2026-2033): 12.3%
Three ways to get this report
Buy it, customize it, or ask a question.Ask an Analyst
Analyst response in 1 business day
- AccessReport author, directly
- Reply timeWithin 1 working day
- No sales callDirect answer only
- FormatEmail reply
- CostFree, no cost
Get the Full Report
What the study covers
- FormatsPDF · Excel · Dashboard
- Timeline2026–2033 annual, 2025 base
- Coverage20+ countries, 5 regions
- Companies10+ key players profiled
Customize the Report
20% free customization
- IncludeCountries, segments, points
- TailorTo your product definition
- ExtendDeeper competitor detail
- OrA fully bespoke study
- Turnaround5–10 working days
Key drivers include advancements in drug development, such as neuroprotective therapies, RNA-based treatments, and improved drug delivery systems. Rising awareness, supportive government initiatives, and reimbursement policies further promote treatment adoption. Additionally, a robust pipeline of innovative therapies addressing motor and non-motor symptoms expands market potential, aligning with the growing patient base.These increasing prevalence rates, rising diagnostic cases, and significant healthcare costs underscore a growing demand for advanced therapies and innovative solutions, driving the expansion of the market. According to the Parkinson’s Foundation (2024), nearly one million people in the U.S. currently live with Parkinson’s disease (PD), projected to rise to 1.2 million by 2030. Globally, over 10 million are affected. Annually, about 90,000 new U.S. cases are diagnosed, with men 1.5 times more likely to develop PD. Annual U.S. costs total USD 52 billion, including USD 2,500 for medications and up to USD 100,000 for surgery per patient. Studies reveal prevalence increases with age and varies by region, with higher rates in the Rust Belt. These findings, published by the Parkinson’s Foundation and The Michael J. Fox Foundation in 2022, emphasize the growing need for research and advanced treatments.
To learn more about this report, Download Free Sample Report According tothe National Institute of Neurological Disorders and Stroke (NINDS) (last reviewed September 20, 2024), PD affects 500,000 to 1 million Americans, causing motor issues like slowness and rigidity, alongside non-motor symptoms such as sleep disturbances and mood changes. While current treatments improve movement, they have limited efficacy in addressing other symptoms or halting disease progression. In 2022, NINDS allocated USD 125 million of the USD 259 million NIH budget for PD research, supporting initiatives like biomarker discovery and translational research. Programs include the Morris K. Udall Centers and the Accelerating Medicine Partnership, aimed at advancing therapeutic development for PD. The investment in PD research by institutions such as NINDS drives advancements in biomarker discovery, translational research, and innovative therapies. These efforts expand treatment options, improve patient outcomes, and fuel growth in the market by addressing unmet medical needs.
The strategic initiatives, including product launches and ongoing research efforts, play a key role in expanding the market for advanced treatments for Parkinson's disease by introducing novel therapies and enhancing existing treatment options. In October 2024, AbbVie revealed that the U.S. FDA had approved VYALEV (foscarbidopa and foslevodopa), a pioneering 24-hour continuous subcutaneous infusion therapy of levodopa for adults with advanced PD.The approval follows positive results from the Phase 3 M15-736 study, which demonstrated that VYALEV significantly improves motor fluctuations, increasing "on" time without troublesome dyskinesia compared to oral carbidopa/levodopa. This therapy offers a continuous, personalized delivery of levodopa, addressing the challenges faced by patients as the disease progresses. VYALEV’s approval represents a significant advancement, as current treatments often become less effective over time, leading to the need for surgical interventions.
The studies found that VYALEV provided superior improvements in motor control, reducing "off" time and improving quality of life. It also showed a favorable safety profile, with common adverse reactions, including infusion site events, hallucinations, and dyskinesia. Coverage for Medicare patients is expected by mid-2025. AbbVie aims to expand access to VYALEV globally, as the treatment has already been approved in 35 countries and initiated in over 4,200 patients worldwide.
Market Dynamics
The Parkinson's disease treatment market is experiencing steady growth due to the rising prevalence of Parkinson's disease, increasing life expectancy, and continued demand for therapies that help manage motor and nonmotor symptoms. Levodopa based therapies remain the standard of care, while dopamine agonists, monoamine oxidase B inhibitors, catechol O methyltransferase inhibitors, and other adjunctive treatments continue to support long term disease management. The market is also witnessing increased focus on formulations that improve symptom control, reduce dosing frequency, and manage fluctuations associated with disease progression. Pharmaceutical companies are investing in disease modifying therapies, gene therapies, and cell based approaches, although most remain in clinical development. Growth is supported by expanding access to neurological care, improved diagnosis, and greater awareness of Parkinson's disease across developed and developing countries. At the same time, treatment costs, limited availability of curative therapies, and the complexity of managing advanced disease continue to influence treatment decisions and shape the overall market environment.
The Parkinson's disease treatment market is primarily driven by the increasing number of people living with Parkinson's disease, particularly among the aging population. The disease requires lifelong treatment, creating sustained demand for medicines that improve motor function and manage disease progression. Healthcare systems are placing greater emphasis on early diagnosis and long term disease management, leading to higher treatment adoption. At the same time, pharmaceutical companies are developing new formulations and drug delivery technologies that improve symptom control and reduce treatment related complications such as motor fluctuations. Continuous innovation in infusion therapies, extended release formulations, and pipeline products is expanding available treatment options for patients with advanced disease. Growing investments in neurology research and supportive regulatory pathways are also encouraging the introduction of new therapies into the market. These factors continue to strengthen the treatment landscape and support market expansion across developed and developing healthcare systems. For instance, in February 2025, Supernus Pharmaceuticals announced that the U.S. Food and Drug Administration approved ONAPGO for adults with advanced Parkinson's disease experiencing motor fluctuations. The approval was supported by a Phase 3 clinical trial involving 107 patients over 12 weeks, and the company stated that the product would become commercially available in the United States during the second quarter of 2025.
The Parkinson's disease treatment market continues to face limitations because currently available therapies primarily manage symptoms rather than slow or stop the progression of the disease. Most patients require lifelong treatment, and therapy becomes more complex as the disease advances. Long term use of levodopa and other medicines is associated with motor complications, including dyskinesia and wearing off episodes, often requiring frequent dose adjustments and combination therapy. In addition, Parkinson's disease presents with both motor and nonmotor symptoms, making treatment highly individualized and increasing the need for specialist care. Access to neurologists and movement disorder specialists remains uneven across many countries, which can delay diagnosis and limit optimal treatment. Advanced therapies such as infusion systems and device assisted treatments also require specialized clinical infrastructure and patient monitoring, making their adoption more challenging in some healthcare settings. Furthermore, several investigational therapies targeting disease progression remain in clinical development, limiting the availability of treatments that address the underlying neurodegenerative process. These factors continue to restrain broader market expansion despite ongoing therapeutic advancements.
The Parkinson's disease treatment market presents a significant opportunity through the development of therapies that target the underlying disease process rather than only managing symptoms. Current treatment options primarily improve motor and nonmotor symptoms, creating a need for therapies that can delay disease progression or preserve neuronal function. Pharmaceutical and biotechnology companies are increasing investments in gene therapies, cell therapies, neuroprotective agents, and regenerative medicine to address this unmet clinical need. Advances in biomarker research and precision medicine are also improving patient selection for clinical trials and supporting the development of targeted treatment approaches. In addition, the use of digital health technologies and wearable monitoring devices is helping physicians evaluate disease progression more accurately and optimize treatment decisions. Growing collaboration between industry, academic institutions, and research organizations is supporting innovation across the Parkinson's disease pipeline. As clinical research continues to advance and regulatory agencies encourage the development of therapies for neurological disorders, the introduction of disease modifying treatments has the potential to expand available therapeutic options, improve long term patient outcomes, and create new growth opportunities for the Parkinson's disease treatment market.
Analyst Perspective
The Parkinson's disease treatment market is shifting from a market focused primarily on symptom management toward one supported by improved drug delivery systems, continuous infusion therapies, and research into disease modifying treatments. The market is becoming more focused on companies with established neurology expertise, approved Parkinson's disease therapies, and active clinical development programs. AbbVie continues to strengthen its position with advanced infusion therapies, while Supernus Pharmaceuticals has expanded its Parkinson's disease portfolio through new product approvals. Amneal Pharmaceuticals is increasing its presence with treatment options for advanced Parkinson's disease, and H. Lundbeck A/S, Novartis AG, and Cerevel Therapeutics continue to invest in research aimed at improving long term disease management and expanding future treatment options.
Drug Class Insights
Based on drug class, the carbidopa-levodopa segment led the market with the largest revenue share of 28.6% in 2025 due to its long-established efficacy in managing symptoms, particularly tremors, stiffness, and bradykinesia. The combination therapy addresses the brain's dopamine deficiency, improving motor function and quality of life for patients. Its proven track record, widespread availability, and cost-effectiveness make it the first-line treatment for Parkinson's. Additionally, its combination with other drugs in various formulations, such as extended-release versions, provides tailored treatment options. Despite the emergence of newer therapies, Carbidopa-Levodopa remains the cornerstone of Parkinson's disease management due to its long-term success and consistent clinical outcomes.
Dopamine agonists are expected to register moderate growth during the forecast period due to their effectiveness in managing Parkinson's disease symptoms, particularly in patients who experience motor fluctuations or as adjuncts to Carbidopa-Levodopa therapy. These drugs mimic dopamine in the brain, helping to improve motor control and reduce tremors and stiffness. Their growth is driven by increasing Parkinson's disease prevalence and expanding patient populations. However, the growth rate is tempered by the preference for Carbidopa-Levodopa as first-line therapy and the development of newer treatment options, such as gene therapies and advanced deep brain stimulation techniques, which may limit market share expansion.
Distribution Channel Insights
Based on distribution channel, the retail pharmacy segment led the market with the largest revenue share of 41.7% in 2025 and is anticipated to witness the fastest growth over the forecast period due to its widespread accessibility and convenience for patients. Retail pharmacies are the primary distribution channel for prescription medications, including Carbidopa-Levodopa, dopamine agonists, and other treatments for managing Parkinson’s disease symptoms. This segment benefits from a large number of patients seeking ongoing treatment and refills. Additionally, the growing prevalence of Parkinson's disease, coupled with an aging population, drives demand for easily accessible medications. The availability of over-the-counter supplements and supportive therapies in retail pharmacies further contributes to the segment’s strong position in the overall market.
To learn more about this report, Download Free Sample Report The online pharmacy segment is expected to witness moderate growth over the forecast period due to increasing patient preference for the convenience of purchasing medications from home. With the rise of e-commerce platforms and advancements in digital health services, online pharmacies offer a wide range of Parkinson’s disease treatments, including prescription and over-the-counter medications. The growth is also driven by factors such as better accessibility, time savings, and competitive pricing. However, regulatory challenges and limited patient awareness in some regions may moderate the segment's growth. Despite these challenges, the convenience and growing adoption of online platforms fuel its expansion.
Regional Insights
North America dominated the Parkinson’s disease treatment market with the largest revenue share of 38.1% in 2025 due to a combination of factors such as a high prevalence of the disease, advanced healthcare infrastructure, and significant research and development investments. The region benefits from robust healthcare systems and a high rate of early diagnosis, contributing to a larger patient base for Parkinson's treatments. Additionally, the presence of key pharmaceutical companies and government initiatives aimed at improving patient care further supports market growth. The increasing adoption of novel therapies and the rising demand for personalized treatments are expected to sustain North America’s dominance in the market.
To learn more about this report, Download Free Sample Report U.S. Parkinson’s Disease Treatment Market Trends
The Parkinsons Disease Treatment market in the U.S. held the largest share in the North America region in 2025. The U.S. Parkinson’s disease treatment industry holds a significant share in the region, driven by the increasing prevalence of the disease and growing demand for effective therapeutic options. The market benefits from expanding awareness about the therapeutic applications of treatments like carbidopa-levodopa and dopamine agonists. Advancements in drug formulations, along with the growing acceptance of Parkinson’s disease treatments within clinical protocols, are further contributing to market growth. The continuous development of new medications and treatment combinations is expected to enhance the treatment landscape, maintaining the U.S. market's dominance.
Europe Parkinson’s Disease Treatment Market Trends
The Europe Parkinson’s disease treatment industry is experiencing notable growth due to increasing awareness of the condition and growing adoption of therapeutic interventions. The aging population in Europe, which is more susceptible to neurological disorders like Parkinson’s, is a key driver of market demand. Rising healthcare expenditure and advancements in treatment formulations for chronic condition management contribute to market growth. Regulatory support for novel Parkinson’s therapies and expanding treatment options in key markets such as Germany, France, and the UK are expected to enhance the overall market landscape.
The UK Parkinson’s disease treatment market is expected to witness significant growth, driven by an increasing focus on neurological health and rising awareness of the benefits of advanced treatments for Parkinson’s management. The National Health Service (NHS) has integrated Parkinson’s treatments into patient healthcare plans, improving accessibility. UK pharmaceutical companies are developing new Parkinson’s treatment formulations, contributing to market growth. Additionally, government initiatives to improve public health and the availability of advanced Parkinson’s medications support market expansion.
Parkinson’s disease treatment market in Germany holds a prominent share in Europe, driven by its strong healthcare system and increasing demand for effective neurological treatments. The adoption of Parkinson’s treatments for managing motor symptoms and supporting quality of life is expanding, with a growing emphasis on evidence-based therapies. Regulatory support for Parkinson’s therapies and advancements in formulation technologies are contributing to market growth. Additionally, the country’s focus on improving patient access to Parkinson’s treatments through healthcare infrastructure development is expected to continue supporting market expansion.
Asia Pacific Parkinson’s Disease Treatment Market Trends
The Asia Pacific Parkinson’s disease treatment industry is experiencing rapid growth, attributed to rising healthcare expenditure, an aging population, and increased consumer awareness of neurological health. The region’s rising incidence of Parkinson’s, particularly in countries like China, India, and Japan, is contributing to the growing demand for therapeutic options. Government initiatives to improve healthcare access, along with expanding healthcare infrastructure, are supporting market development. The expansion of pharmaceutical companies' product portfolios and distribution networks is expected to enhance market penetration in this region.
China Parkinson’s disease treatment market is witnessing moderate growth due to the increasing prevalence of neurological conditions and the country’s expanding aging population. Government efforts to improve healthcare infrastructure and increase access to neurological treatments foster market development. The growing adoption of Parkinson’s therapies in managing motor symptoms and slowing progression is expected to continue driving demand. The presence of local and international pharmaceutical companies further supports the availability and accessibility of Parkinson’s treatments.
Parkinson’s disease treatment market in Japan is characterized by high consumer awareness and a well-established healthcare system. The growing prevalence of Parkinson’s, coupled with the country’s aging population, is driving demand for therapeutic interventions. Japanese healthcare providers increasingly recommend new treatment options as part of patient care protocols. Ongoing research and developing novel Parkinson’s medications are contributing to market growth. Additionally, collaborations between pharmaceutical companies and healthcare providers are facilitating greater access to Parkinson’s treatments nationwide.
Latin America Parkinson’s Disease Treatment Market Trends
The Latin America Parkinson’s disease treatment industry is experiencing high growth over the forecast period owing to the increasing prevalence of Parkinson's disease, greater awareness, and the rising demand for advanced therapies and drugs. As the population in Latin America continues to age, the incidence of Parkinson's disease is expected to rise, creating a significant demand for treatments.
Brazil Parkinson’s disease treatment market is witnessing steady growth, fueled by an increasing focus on healthcare accessibility and a rising prevalence of neurological conditions. Government policies to improve healthcare coverage and expand access to treatment options support market expansion. The demand for Parkinson’s therapies, particularly for managing motor symptoms and improving quality of life, is increasing. Additionally, growing consumer awareness of Parkinson’s treatment benefits will continue driving the market forward.
Middle East & Africa Parkinson’s Disease Treatment Market Trends
The Middle East and Africa Parkinson’s disease treatment industry is experiencing growth due to rising awareness about neurological health and the increasing prevalence of related conditions. Key markets such as South Africa, UAE, and Saudi Arabia are witnessing an uptick in demand for Parkinson’s treatment options. Governments in the region are focusing on improving healthcare systems and expanding access to medications, further stimulating market growth. Collaborative efforts between healthcare providers and pharmaceutical companies are helping to improve the availability of Parkinson’s treatments, driving market expansion in the MEA region.
The Saudi Arabia Parkinson’s disease treatment market is expanding, driven by increasing healthcare initiatives and a rising focus on neurological condition management. The country’s Vision 2030 framework emphasizes improving health outcomes, contributing to greater demand for effective treatments for Parkinson’s. With an increasing prevalence of age-related conditions, Parkinson’s treatments are becoming an essential part of patient care protocols. The government’s efforts to improve healthcare infrastructure and drug accessibility, along with growing awareness of the condition, are expected to support market growth. Key international and local pharmaceutical companies are expanding their regional offerings, enhancing availability and competition.
Key Parkinson’s Disease Treatment Company Insights
The Parkinson’s disease treatment industry is competitive, with key players such as AbbVie, Merck, and GlaxoSmithKline leading the market through their established product portfolios, including Carbidopa-Levodopa and dopamine agonists. Companies are focusing on innovation, including the development of advanced formulations, combination therapies, and personalized treatments. New entrants are challenging market leaders with novel drug candidates, while ongoing research and clinical trials further intensify competition. Additionally, strategic partnerships, mergers, and acquisitions are common as companies seek to expand their market presence and enhance R&D capabilities. The market's growth is driven by continuous advancements in therapeutic options and improving patient outcomes.
Key Parkinson’s Disease Treatment Companies:
The following key companies have been profiled for this study on the parkinson’s disease treatment market.
- Cerevel Therapeutics
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- GlaxoSmithKline plc. (GSK)
- AbbVie, Inc.
- H. Lundbeck A/S
- Amneal Pharmaceuticals LLC
- Supernus Pharmaceuticals, Inc.
Competitive Benchmarking
Category
Operating Strategies
Competitive Edge
Weakness
Established Players (Novartis AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., GlaxoSmithKline plc., H. Lundbeck A/S)
- Focus on maintaining Parkinson's disease portfolios through approved therapies, lifecycle management, and expansion into advanced treatment options. Invest in clinical research, strategic collaborations, and geographic expansion while strengthening relationships with neurologists, specialty clinics, hospitals, and retail pharmacy networks.
- Broad product portfolios and established presence in neurology support long term market participation. Strong regulatory experience, global manufacturing capabilities, and extensive distribution networks enable consistent product availability across major healthcare markets.
- High research and development costs associated with neurological drug development. Dependence on mature products and lengthy regulatory timelines can delay the introduction of new therapies. Competition from generic medicines and pricing pressure may also affect portfolio growth.
Emerging Players (Cerevel Therapeutics, Amneal Pharmaceuticals LLC, Supernus Pharmaceuticals, Inc.)
- Focus on developing differentiated therapies for motor fluctuations and other unmet needs in Parkinson's disease through clinical research, innovative drug delivery technologies, and targeted product launches. Expand market presence through strategic partnerships, licensing agreements, and focused commercialization in key markets.
- Ability to introduce therapies with differentiated mechanisms of action and specialized formulations for Parkinson's disease management. Agile development processes and focused neurology portfolios enable faster response to evolving clinical needs and treatment gaps.
- Limited commercial infrastructure and geographic reach compared with larger pharmaceutical companies. Dependence on a smaller number of products and ongoing clinical development increases operational and regulatory risk.
Recent Developments
-
In October 2024, MeiraGTx reported favorable outcomes from its AAV-GAD clinical bridging study for Parkinson's disease, achieving both safety and efficacy goals. The high-dose group showed an 18-point improvement in the UPDRS Part 3 score at 26 weeks, while both high and low-dose groups exhibited significant improvements in the PDQ-39 score, a measure of quality of life. The treatment was well-tolerated, with no serious adverse events, reinforcing the move toward Phase 3 trials.
-
In September 2024, Amneal Pharmaceuticals introduced CREXONT (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson's disease. The product features a unique formulation that combines immediate-release granules with extended-release pellets, offering a longer duration of effective symptom control with fewer doses compared to traditional immediate-release options. CREXONT is now available in U.S. pharmacies and is supported by affordability services. Amneal plans to present CREXONT at the International Congress of Parkinson's Disease and Movement Disorders in September 2024. The medication is intended to effectively manage Parkinson's symptoms.
-
In September 2024, AbbVie reported positive topline results from the Phase 3 TEMPO-1 trial assessing tavapadon as a monotherapy for early Parkinson's disease. The trial showed a statistically significant improvement in the combined MDS-UPDRS Parts II and III score at week 26 for both the 5 mg and 15 mg doses of tavapadon. The treatment also met important secondary endpoints, demonstrating significant improvements in motor aspects of daily living. The safety profile was consistent with previous studies. Full data will be shared at upcoming medical conferences.
Parkinson’s Disease Treatment Market Report Scope
Report Attribute
Details
Market size value in 2025
USD 5.6 billion
Market size value in 2026
USD 6.3 billion
Revenue forecast in 2033
USD 14.2 billion
Growth rate
CAGR of 12.3% from 2026 to 2033
Historical data
2021 - 2024
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million/billion, and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Drug class, distribution channel, region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Norway; Sweden; Japan; China; India; South Korea; Australia; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait.
Key companies profiled
Cerevel Therapeutics; Novartis AG; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; GlaxoSmithKline plc. (GSK); AbbVie, Inc.; H. Lundbeck A/S; Amneal Pharmaceuticals LLC; Supernus Pharmaceuticals, Inc.
Customization scope
Free report customization (equivalent up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Parkinson’s Disease Treatment Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global Parkinson’s disease treatment market report based on drug class, distribution channel, and region:
To learn more about this report, Download Free Sample Report -
Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
-
Carbidopa-Levodopa
-
Dopamine Agonists
-
MAO-B Inhibitors
-
COMT inhibitors
-
Anticholinergics
-
Others
-
-
Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
-
Hospital Pharmacy
-
Retail Pharmacy
-
Online Pharmacy
-
-
Regional Outlook (Revenue, USD Million, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
South Korea
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East and Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Research Methodology
The parkinson’s disease treatment market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each parkinson’s disease treatment segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment - Drug Class
Revenue capture definition
Carbidopa Levodopa
This segment includes combination therapies containing levodopa and carbidopa that are prescribed to restore dopamine levels and manage motor symptoms associated with Parkinson's disease. It includes immediate release, controlled release, extended release, enteral suspension, and other approved formulations containing this combination and excludes products classified under other pharmacological classes.
Dopamine Agonists
This segment includes therapies that directly stimulate dopamine receptors to improve motor function in patients with Parkinson's disease. It covers oral, transdermal, and injectable dopamine agonists approved for Parkinson's disease treatment and excludes medicines containing levodopa or other pharmacological classes.
MAO B Inhibitors
This segment includes monoamine oxidase B inhibitor therapies that increase dopamine availability by reducing its breakdown in the brain. It includes products used as monotherapy or in combination with other Parkinson's disease treatments and excludes products primarily classified under other drug classes.
COMT Inhibitors
This segment includes catechol O methyltransferase inhibitor therapies that prolong the therapeutic effect of levodopa by reducing its peripheral metabolism. The segment includes approved adjunctive treatments used with levodopa containing regimens and excludes products assigned to other pharmacological classes.
Anticholinergics
This segment includes anticholinergic therapies indicated for the management of tremor and selected motor symptoms in Parkinson's disease through central cholinergic inhibition. It includes approved anticholinergic medicines used in Parkinson's disease treatment and excludes products classified under other drug classes.
Others
This segment includes all approved pharmacological therapies for Parkinson's disease that are not classified under Carbidopa Levodopa, Dopamine Agonists, MAO B Inhibitors, COMT Inhibitors, or Anticholinergics. Revenue is assigned based on the product's primary pharmacological class, ensuring complete market coverage without overlap.
Segment - Distribution Channel
Revenue capture definition
Hospital Pharmacy
This segment includes Parkinson's disease therapies dispensed through hospital based pharmacies for inpatients and outpatients receiving treatment within hospital affiliated healthcare facilities. It excludes products dispensed through retail or online pharmacy channels.
Retail Pharmacy
This segment includes Parkinson's disease therapies dispensed through community pharmacies, chain pharmacies, and independent retail pharmacies for outpatient use based on valid prescriptions. It excludes medicines supplied through hospital based or online pharmacy channels.
Online Pharmacy
This segment includes Parkinson's disease therapies dispensed through licensed online pharmacy platforms that process prescriptions and supply medicines directly to patients through home delivery or approved collection services. It excludes products distributed through hospital or retail pharmacy channels.
Estimation Model
To learn more about this report, Download Free Sample Report The Parkinson's disease treatment market was estimated using an epidemiology based market analysis approach. Country level prevalence data for Parkinson's disease were collected from peer reviewed publications, government health agencies, and neurological associations. The patient pool was refined by estimating diagnosed and treated patients across major regions. Treated patients were further segmented by drug class, including carbidopa levodopa, dopamine agonists, MAO B inhibitors, COMT inhibitors, anticholinergics, and other therapies, based on prescribing patterns and treatment guidelines. The average annual cost of therapy for each drug class was determined using public pricing databases, company information, and healthcare sources. Market estimates were generated by multiplying the treated patient population receiving each therapy by the corresponding annual treatment cost. The findings were validated through secondary research, prescription trends, company product portfolios, regulatory approvals, and interviews with neurologists and industry participants to ensure consistency across regional markets.
Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
Parkinson's Disease Treatment Competitive Landscape & Pipeline Assessment
Conducted a targeted assessment of the global Parkinson's disease treatment market, evaluating approved therapies, late-stage pipeline products, drug delivery technologies, and emerging disease modifying approaches. The study analyzed key companies including AbbVie Inc., Supernus Pharmaceuticals, Amneal Pharmaceuticals, H. Lundbeck A/S, Novartis AG, Teva Pharmaceutical Industries Ltd., Cerevel Therapeutics, Merck & Co., Inc., and GlaxoSmithKline plc. The assessment also reviewed clinical development activities, strategic collaborations, and treatment trends across different stages of Parkinson's disease.
Helped the client identify growth opportunities across established and emerging therapies, evaluate competitive positioning, benchmark product pipelines, and prioritize partnership, licensing, and portfolio expansion opportunities within the Parkinson's disease treatment market.
Parkinson's Disease Treatment Technology & Product Benchmarking Study
Delivered a detailed benchmarking assessment of Parkinson's disease treatment technologies, focusing on oral therapies, infusion therapies, transdermal formulations, and investigational gene and cell therapies. The study compared product characteristics, clinical development status, treatment approaches, regulatory progress, and differentiation across leading manufacturers while assessing the potential of new therapeutic platforms.
Enabled the client to evaluate technology positioning, identify product differentiation opportunities, assess treatment gaps, and support research and product development decisions aligned with evolving clinical needs in Parkinson's disease management.
Parkinson's Disease Treatment Manufacturing & Supply Chain Assessment
Conducted a strategic assessment of the Parkinson's disease treatment manufacturing ecosystem, evaluating active pharmaceutical ingredient production, finished dosage manufacturing, supply chain capabilities, regulatory compliance, contract manufacturing opportunities, and regional production capacity. The study also reviewed distribution models supporting oral, injectable, infusion, and specialty neurological therapies across major markets.
Supported manufacturing and supply chain planning by identifying production capabilities, evaluating outsourcing opportunities, assessing supply chain risks, and strengthening long term product availability and distribution strategies for Parkinson's disease therapies across global markets.
Frequently Asked Questions About This Report
The global Parkinson's disease treatment market size was valued at USD 5.6 billion in 2025 and is estimated at USD 6.3 billion for 2026.
The Carbidopa-Levodopa segment led the market with the largest revenue share of 28.6% in 2025.
The Retail Pharmacy segment held the largest revenue share of 41.7% in 2025.
Major trends include the development of disease-modifying therapies, advancements in gene and cell therapies, increasing adoption of continuous infusion and extended-release formulations, precision medicine approaches, and the integration of digital health and wearable monitoring technologies.
Key players include Cerevel Therapeutics, Novartis AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., GlaxoSmithKline plc. (GSK), AbbVie Inc., H. Lundbeck A/S, Amneal Pharmaceuticals LLC, and Supernus Pharmaceuticals, Inc.
The global Parkinson's disease treatment market is expected to grow at a CAGR of 12.3% from 2026 to 2033, reaching USD 14.2 billion by 2033.
Key factors include the rising prevalence of Parkinson's disease, growing aging population, increasing adoption of advanced drug delivery systems, continued innovation in disease-modifying therapies, and expanding access to neurological care and early diagnosis.
North America dominated the Parkinson's disease treatment market with a 38.1% revenue share in 2025.
Asia Pacific is the fastest-growing regional market over the forecast period.
About the Author(s)
Pharmaceuticals Research Team
Healthcare · PharmaceuticalsThis report was authored by the pharmaceuticals research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the pharmaceuticals segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
